ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update"
Episode Synopsis
Shaking up an underwhelming year for fresh biotech paper, a trio of biotechs filed to go public on NASDAQ last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the IPO filings by MBX and Massachusetts companies Zenas and Bicara. Washington Editor Steve Usdin returns to the podcast to provide updates on the Inflation Reduction and Biosecure acts, as well as the life sciences policies of presidential candidates Donald Trump and Kamala Harris. And Director of Biopharma Intelligence Karen Tkach Tuzman zeroes in on the latest trends among pharma’s deals with biotechs over the past 12 months and the latest start-up out of Versant Ventures, Borealis.View full story: https://www.biocentury.com/article/65335400:00 - Introduction01:48 - Biotech IPOs12:48 - Washington Update20:39 - Versant, Novartis Newco24:34 - Pharma-Biotech Deal TrendsReach us by sending a text
More episodes of the podcast BioCentury This Week
Ep. 324 - Genmab, GSK and Drug Pricing
29/09/2025
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
15/09/2025
In God we trust